5 Ethical Considerations in Healthcare Research

A crucial ethical consideration in oncology research is ensuring truly informed consent, particularly guarding against therapeutic misconception - when patients believe participation equates to guaranteed personal benefit. In my work, I address this by using clear, jargon-free explanations of study purpose, risks, benefits, and alternatives, informed by frameworks like the Belmont Report and Declaration of Helsinki. I also incorporate structured consent conversations that emphasize patient autonomy, provide opportunities for questions, and reassess understanding, especially in early-phase or genomic trials where treatment expectations can be blurred. This approach ensures patients make voluntary, well-informed decisions while we uphold respect, beneficence, and justice throughout our research processes.

As someone leading a healthcare IT company, one ethical consideration that consistently shapes our work is algorithmic bias in AI tools, especially those used in diagnostics or patient risk prediction. In a space where every insight can influence life-altering decisions, bias isn't just a technical glitch — it's a trust and safety issue.

We've seen how even well-intentioned models can fail. One real-world example that stuck with me was the case of a widely-used hospital algorithm that underestimated Black patients' health needs by over 50% — not due to malice, but because it used past healthcare spending as a proxy for need. That moment reinforced a belief we live by: bias in, bias out.

To address this, we rigorously audit our training data for demographic gaps, apply explainability tools like SHAP to ensure transparency, and always involve clinicians during testing. Our finance and compliance teams also keep us aligned with HIPAA and the FDA's AI/ML SaMD guidance, ensuring both ethical and financial accountability.

In healthcare, the stakes are too high for shortcuts. By taking the slower, more thoughtful route, we've found that trust scales faster than technology ever can.

Dr. Shamsa Kanwal is a Consultant Dermatologist and Aesthetic Physician with over 10 years of experience in clinical practice and research.

One ethical consideration that's particularly important in dermatology, especially in aesthetic research, is ensuring informed consent with full transparency about risks, benefits, and limitations of emerging treatments.

In cosmetic dermatology, patients are often influenced by social media trends and may have unrealistic expectations. When conducting research or evaluating new technologies, I make it a priority to communicate clearly about what is evidence-based and what is still investigational. This includes discussing potential side effects, the quality of supporting data, and the difference between aesthetic improvement and medical necessity.

By prioritizing patient education and informed decision-making, I help ensure that research participation and clinical care are both ethical and grounded in trust.

One of the most critical ethical considerations in my area of healthcare—particularly within ketamine-assisted therapy and psychedelic-informed mental health treatment—is informed consent that extends beyond legality into deep understanding and emotional readiness.

Ketamine is a powerful neuroplastic agent, and while it has incredible potential to unlock healing, it also places patients in highly vulnerable states—emotionally, cognitively, and sometimes spiritually. In this altered state of consciousness, patients may revisit trauma, experience ego dissolution, or undergo profound psychological shifts. The ethical imperative, then, is not just to explain the risks and benefits on paper, but to ensure the patient fully grasps the psychological depth of the experience and consents to the emotional terrain they may encounter.

In my work, we address this through what I call therapeutic consent, not just clinical consent. We have extended preparatory sessions where we explore a patient's history, expectations, fears, and goals—not only for safety but to empower agency. We also incorporate integration sessions post-treatment to help patients process their experiences and apply the insights meaningfully. This ensures that consent is ongoing, not just a one-time checkbox.

Ethically, it's our responsibility to hold space not only for physical safety, but for emotional dignity. Healing must be led by the patient, not imposed by the provider. My job is to facilitate a process that is deeply human, not just medical.

One ethical consideration that weighs heavily in the addiction treatment field—especially when it comes to research and data—is how we handle consent and transparency when dealing with vulnerable populations. At Ridgeline Recovery, we serve individuals at one of the most fragile moments in their lives. That means any type of data collection—whether it's for internal outcomes research, treatment efficacy, or quality improvement—has to be approached with more than just a signed waiver. It demands respect, clarity, and a human touch.

Too often, clients in early recovery feel pressure to agree to things they don't fully understand, just to keep their treatment going. That's a line we won't cross. Anytime we collect data for research or program development, we go beyond the paperwork. We take the time to explain, in plain language, what we're gathering, why it matters, and how it will (and won't) be used. Participation is always optional, and we make sure opting out doesn't affect their care in any way.

We also involve our clinical team in reviewing any proposed research processes, even if it's in-house, to ensure it aligns with our trauma-informed model. If it feels extractive or misaligned with our values—even if it could give us a "better" metric—we scrap it.

Here's what I've learned: ethics in research isn't just about IRB approvals or compliance. It's about protecting dignity. These are people, not data points. And the trust they place in us isn't just part of the care—it is the care.